MedTrace Logo

Efficacy and Safety of Tocilizumab in Adult's Still Disease

NCT01002781 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-10-27

No results posted yet for this study

Summary

Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever, arthritis, rash, and acute phase response often requiring high dose corticosteroids. In view of several case reports which have shown dramatic improvement in patients treated with Tocilizumab and a phase 2 study of this drug in children with Still's disease, the objective of the current study is to assess the efficacy and safety of Tocilizumab in patients with adult's Still disease.

Conditions

  • Adult's Still Disease

Interventions

DRUG

Tocilizumab

Tocilizumab, IV, 8 mg/kg, every 2 weeks

Sponsors & Collaborators

  • Rambam Health Care Campus

    collaborator OTHER

  • Assaf-Harofeh Medical Center

    collaborator OTHER_GOV

  • Bnai Zion Medical Center

    collaborator OTHER_GOV

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002781 on ClinicalTrials.gov